NCT05244577 is a Phase 3 clinical trial of Olanzapine Tablets in Olanzapine, sponsored by Shi Yanxia.

Who is sponsoring NCT05244577?

NCT05244577 is sponsored by Shi Yanxia.

What drugs are being tested in NCT05244577?

Interventions in NCT05244577: Olanzapine Tablets, Placebo.

What condition does NCT05244577 study?

NCT05244577 studies Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin.

Is NCT05244577 still recruiting?

NCT05244577 is currently status unknown. Last updated 6 February 2023.

Last reviewed 2023-02-06 · How we verify

NCT05244577

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer

Status unknown Phase 3 Last updated 6 February 2023

What this trial tests

Phase 3 trial testing Olanzapine Tablets in Olanzapine in 75 participants. Status unknown.

Timeline

18 January 2022

Primary endpoint
31 December 2023

31 March 2024

Quick facts

Lead sponsor	Shi Yanxia
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	75
Start date	18 January 2022
Primary completion	31 December 2023
Estimated completion	31 March 2024
Sites	1 location across China

Drugs / interventions tested

Olanzapine Tablets — full drug profile →
Placebo

Conditions studied

Olanzapine — all drugs for Olanzapine →
CINV — all drugs for CINV →
Testicular Cancer by AJCC V6 and V7 Stage — all drugs for Testicular Cancer by AJCC V6 and V7 Stage →
Cisplatin — all drugs for Cisplatin →

Sponsor

Shi Yanxia — full company profile →

Who can join

16 and older, male only, with Olanzapine or CINV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the efficacy and safety of olanzapine combined with fosaprepitant, ondansetron and dexamethasone compared with placebo combined with fosaprepitant, ondansetron and dexamethasone in the prevention of nausea and vomiting in germ-cell tumors receiving 5-day cisplatin chemotherapy

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Olanzapine Tablets

Trials testing the same drug.

NCT07035821 — Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy · Phase 3 · not yet recruiting

Other recruiting trials for Olanzapine

Currently open trials in the same condition.

NCT07403370 — Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis · recruiting
NCT06338683 — Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer · Phase 3 · recruiting
NCT04892199 — Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Me · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05244577 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shi Yanxia
Last refreshed: 6 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05244577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing